HIV Excellence Forum

By Edan Stanley Mitch DeKoven, MHSA, senior principal, health economics/outcomes research, real world insights, IQVIA, explains that while payers are used to certain mandates—such as the latest measures requiring health plans to provide access to preventive…

By Edan Stanley Charles M Karnack, PharmD, BCNSP, adjunct assistant professor of clinical pharmacy at Duquesne University in Pittsburgh, PA, explains common challenges faced by the payer market regarding preventive HIV care, lists potential fixes to improve…

Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to provide access to…

By Russell Spjut, PharmD, owner of Formulary Intel Consulting Recent updates to preventive measures recommended by the US Preventive Services Task Force (USPSTF) seek to open access to HIV preventive treatment; though the rollout may be confusing for some…

Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational HIV-1…

Researchers reveal that the proportion of qualified health plans that require prior authorization for HIV PrEP is highest in the South, suggesting this may be a barrier to access in the region arguably in most need of the drug. In a paper published June 3 in…

HIV is still a major public health problem in the United States. Data from the Centers for Disease Control and Prevention (CDC) estimate that 1.1 million persons in the United States are currently living with HIV,1 including an estimated 15% of individuals…